Expertise PartnerApplied BioMath applies mechanistic modeling to drug R&D to help biotechnology and pharmaceutical companies answer questions and make decisions for the advancement of drug candidates. A team of mathematicians, biologists, clinical pharmacologists and pharmaceutical industry experts, they leverage biology, mathematics, proprietary technologies, HPC, and industry experience to perform massive scale simulations which enable groups to determine best-in-class properties of a clinical candidate, reduce attrition rates, and identify key differentiators from competitors. www.appliedbiomath.com
Hinge Bio is leveraging its proprietary Flex-Hinge™ antibody platform to develop the next-generation of bispecific and multispecific antibodies that bind with multi-handed cooperativity to both disease targets and effector cells. Hinge Bio’s streamlined chemical ligation process technology enables the production of therapeutic candidates with orders-of-magnitude improved affinity and specificity, incorporating virtually any polypeptide, including gold standard targeting domains such as natural, unmodified Fabs, and effector molecules including growth factors, cytokines, receptor decoys and apoptosis agonists.
Invicro, a Konica Minolta company is a leading provider of in vivo and ex vivo imaging services and software. Founded in 2008, the company’s mission is to improve the role and function of imaging in drug discovery across all therapeutic areas and phases. As part of the Konica Minolta Precision Medicine Initiative, the company’s innovative quantitative tissue biomarker services help accelerate the discovery and development of more personalized therapies.
Ligand’s OmniAb® therapeutic antibody platforms produce highly diversified, fully human antibody repertoires optimized in vivo for manufacturability, therapeutic efficacy and reduced immunogenicity – Naturally optimized human antibodies®. The single-license OmniAb offering is the industry’s only with three species and multiple genetic backgrounds – 3 species, 1 license™.
CytomX Therapeutics is a clinical-stage oncology biopharmaceutical company pioneering a novel class of investigational antibody therapeutics based on its Probody™ therapeutic technology platform. Probody therapeutics are designed to exploit unique conditions of the tumor microenvironment to more effectively localize antibody binding and activity while minimizing activity in healthy tissues. CytomX and its partners have four potentially best in class or first in class cancer immunotherapies in the clinic against both clinically validated and novel targets.
Ab Studio Inc.
Ab Studio Inc. is a biotech platform start-up combining computer aided design (CAAD) with traditional hybridoma and phage display technologies to develop novel therapeutic antibodies targeting cancer and CNS diseases. Based on the combination of CAAD and traditional technologies, we developed three new antibody discovery platforms including our unique “imbalanced” bispecific antibody platforms. We will apply case studies to demonstrate how this new platform could be applied to develop bispecific antibodies with the best safety, efficacy and developability balance.
MabPlex International provides onestop, high-quality CRO/CMO solutions for biologics (mAb and ADCs) to our global clients. We are dedicated to help our clients accelerate development process and reduce manufacture costs. MabPlex has extensive experiences in manufacturing for therapeutic antibodies and antibody-drug conjugates (ADCs). Our manufacturing facilities with large-scale disposable lines and world-class instruments are operated by well-trained professionals in full compliance with U.S, European, and Chinese GMP regulations.